(The Hindu Business Line Aug 10 2008) Strong performance in branded finished dosages, growth momentum in exports and a strong position in anti-malarial drugs makes Ipca Labs, a medium sized pharma company with Rs 1,100 crore revenues, a good investment option. At the current market price of Rs 567, the stock trades at 8 times its 2008-09 earnings per share; at a discount to like-sized peers such as Torrent Pharmaceuticals and Matrix Labs. Ipca has a diversified business strategy that minimises risks, both segment and geography-wise. In the last five years, Ipca Labs has grown revenues at annualised rate 19 per cent while profits have edged up 12 per cent. The company has been able to maintain operating margins of over 20 per cent even as it has heavily invested in building capacities and expanding facilities, which is a positive. The company has chosen to take a differentiated approach to acquire a front end presence in various markets. This is best exemplified by its tie-up with Ranba...
This is my investment scrapbook. My request to viewers would be to use their own judgment before taking call on any shares mentioned here. Moreover, although I always try to be accurate and correct , there is no guarantee of the accuracy and correctness of the information provided here. Viewers would be using information provided here at their own risk. I won't be liable for any loss whatsoever for transaction based on the information provided here.